Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study.
about
Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular DiseaseOsteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.Serum osteoprotegerin and renal function in the general population: the Tromsø Study.Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patientsEndothelial cells obtained from patients affected by chronic venous disease exhibit a pro-inflammatory phenotype.Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis.Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney diseaseOsteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse.Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients.Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.Osteoprotegerin levels in ST-elevation myocardial infarction: Temporal profile and association with myocardial injury and left ventricular functionPlasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin.Osteopontin regulates macrophage activation and osteoclast formation in hypertensive patients with vascular calcification.The role of osteoprotegerin in cardiovascular disease.Prediction of Fractures and Major Cardiovascular Events in Men Using Serum Osteoprotegerin Levels: The Prospective STRAMBO Study.Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study.Osteoprotegerin as a marker of cardiovascular risk in children and adolescents with type 1 diabetes.Triglyceride Levels and Fracture Risk in Midlife Women: Study of Women's Health Across the Nation (SWAN).Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants.Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men.Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients.High osteoprotegerin levels predict MACCE in STEMI patients, but are not associated with myocardial salvage.Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trialCigarette smoking and the risk of venous thromboembolism: The Tromsø Study
P2860
Q26747224-34DA5898-57D9-4107-9605-1666A2B9F50EQ27692635-8E0E5B6D-A3C1-4AD2-B55D-6DAF1D638122Q33793497-446E06E2-BA38-41BA-BA7F-CEC9605604CDQ33882341-B1D77591-B39E-4E90-8D40-E417689D784AQ34318454-1C8B4D6A-5C6A-4271-9286-7DFED7169CF0Q34412603-63285937-D6AD-4096-A8A2-091D53F575FFQ34502634-7AAA98EB-F4DD-4B87-BDB5-A80FEE75CE61Q34550560-8CA67E1C-A82B-4CBB-A029-5DA0F49F7BACQ35935297-797765EE-F86D-4763-AB34-E63735CE31B3Q36273402-6DB0595D-92FB-497B-A753-1E961C4C362AQ36295418-87572D39-6A6C-4355-B6E2-2821BD73CA6AQ36388215-7433A9FE-4A09-4A95-9305-FF94C021B153Q37408169-F5365951-D783-4AD7-B859-4EF0FBDF37B3Q37587576-43F04A54-9442-44AB-8A91-E760E3F6B636Q38056541-CABABC4B-34C6-4FD7-AC5F-57AA7E7B28D9Q38693577-697C0A5C-47F6-465A-AC25-3B2843254EF2Q39090351-6763F282-55C6-444F-BB26-279A298F05ACQ39824391-AF19FA7A-84D4-41A5-8208-4FCE9B60BE7DQ40705019-517FF634-9805-46BD-AE9A-22C2228E475FQ41513500-C3DD02A6-4BEE-449E-BA6B-1F47AB2161D6Q42013167-915FF566-92D3-4F42-B0FF-C7879EBA7A6BQ48353042-59D2D318-6FFE-4BFC-AF12-963E95F22E25Q53068399-7ACACE8F-3E64-4516-BED1-46AD8BEB698BQ57389466-B8C6C09D-732E-4B2B-8E5C-511FED808919Q57788361-D1E7C29A-9E88-4B84-8DD8-C2A7C1C38F16
P2860
Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromsø Study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Serum osteoprotegerin is a pre ...... population: the Tromsø Study.
@en
Serum osteoprotegerin is a pre ...... population: the Tromsø Study.
@nl
type
label
Serum osteoprotegerin is a pre ...... population: the Tromsø Study.
@en
Serum osteoprotegerin is a pre ...... population: the Tromsø Study.
@nl
prefLabel
Serum osteoprotegerin is a pre ...... population: the Tromsø Study.
@en
Serum osteoprotegerin is a pre ...... population: the Tromsø Study.
@nl
P2093
P2860
P1476
Serum osteoprotegerin is a pre ...... population: the Tromsø Study.
@en
P2093
P2860
P304
P356
10.1111/J.1538-7836.2011.04222.X
P577
2011-04-01T00:00:00Z